依达拉奉联合舒血宁治疗急性脑梗死30例临床观察

目的 探讨依达拉奉联合舒血宁治疗急性脑梗死临床疗效.方法 将60例急性脑梗死患者随机分为观察组和对照组,对照组应用一般治疗+舒血宁,观察组在对照组基础上加用依达拉奉.分别对两组治疗前、治疗14d后的神经功能缺损程度及临床疗效进行评价.结果 两组治疗后的神经功能缺损较治疗前均有明显改善,观察组优于对照组,差异有统计学意义(P＜0.01);观察组总有效率为87.5%,高于对照组的60.0%,差异有统计学意义(P＜0.05).结论 依达拉奉联合舒血宁治疗急性脑梗死能保护脑细胞,有效改善神经功能缺损.     

注射用血栓通(冻干)治疗急性缺血性脑卒中的临床研究

目的观察注射用血栓通(冻干)治疗急性缺血性脑卒中的临床疗效。方法将200例急性缺血性脑卒中病人随机分为试验组和对照组,每组100例。对照组给予常规治疗,试验组在对照组基础上加用注射用血栓通(冻干)治疗。比较两组神经功能缺损(NIHSS)评分、巴氏指数(BI)、改良Rankin量表(mRS)评分、生存质量评分(SS-QOL)。结果治疗后试验组NIHSS、BI评分改善程度优于对照组(P0.05);两组SS-QOL评分均较治疗前明显升高,但组间比较差异无统计学意义(P0.05)。结论注射用血栓通(冻干)可明显改善急性缺血性脑卒中病人的神经功能缺损程度及活动能力。     

舒血宁注射液治疗急性脑梗死临床观察

目的评价舒血宁注射液治疗急性脑梗死的临床效果及对血管内皮的保护和抗自由基作用.方法将60例急性脑梗死病人用抛币法随机分为舒血宁治疗组和维脑路通对照组,观察两组治疗前后一氧化氮(NO)、内皮素(ET)、超氧化物歧化酶(SOD)、丙二醛(MDA)含量变化,神经功能缺损评分及日常生活活动量表(ADL)评分的变化.结果舒血宁组在治疗14 d后NO、ET、MDA的含量降低,SOD含量升高;神经功能缺损评分下降和ADL评分下降均有显著差异.结论舒血宁注射液能保护血管内皮功能,清除自由基,改善脑血液循环,减轻脑梗死病人神经功能缺损,提高病人独立生活能力.     

益气活血法联合电针治疗急性缺血性脑卒中

目的：观察益气活血法联合电针治疗急性缺血性脑卒中的临床疗效。方法将92例缺血性脑卒中患者随机分为治疗组（50例）和对照组（42例）,两组均给予西医神经内科常规治疗。治疗组采用益气活血法联合电针治疗,对照组给予舒血宁注射液20 mL加5%葡萄糖注射液或生理盐水250 mL每日1次静脉滴注。两组均治疗1个月观察临床疗效,于治疗前后评价 NIHSS评分,同时采用简式Fugl meyer运动量表（FMMS）评定神经功能。结果两组治疗后NIHSS评分、FMMS评分均较治疗前明显改善（P〈0.05或P〈0.01）;治疗组治疗后 NIHSS评分、FMMS评分均较对照组明显改善（P〈0.05或P〈0.01）。治疗组临床疗效总有效率为94.0%,对照组为78.6%,治疗组临床疗效总有效率明显优于对照组（P〈0.05）。结论益气活血法联合电针治疗急性缺血性脑卒中可明显改善患者神经功能缺损程度,且优于单纯西药治疗。     

舒血通注射液联合舒血宁注射液治疗急性脑梗死的疗效观察

目的观察疏血通注射液联合舒血宁注射液治疗急性脑梗死（ACI）的临床疗效。方法将200例急性脑梗死患者随机分成治疗组和对照组,各100例。治疗组用疏血通注射液6mL、舒血宁注射液注射液20mL静脉输注,对照组采用舒血宁注射液注射液20mL静脉输注,两组均每日输注1次,14d为1个疗程。治疗结束后,分析两组患者神经功能缺损评分、临床疗效及安全性。结果治疗组神经功能缺损评分减少程度优于对照组,差异有统计学意义（P〈0.01）;对照组临总有效率为87%,治疗组总有效率67%,两组比较差异有统计学意义（P〈0.05）。两组均无明显不良反应。结论疏血通注射液联合舒血宁注射液治疗急性脑梗死临床效果显著,无明显不良反应。     

舒血宁注射液治疗老年缺血性脑卒中的疗效观察

目的观察舒血宁注射液对老年缺血性脑卒中的治疗效果。方法按就诊时间将200例老年缺血性脑卒患者分为治疗组（100例）与对照组（100例）,观察两组疗效。结果治疗组总有效率为74.0%,明显优于对照组的62.0%;舒血宁注射液治疗期间有2例出现不良反应,症状均轻微,不需停药,不影响疗程,部分患者血脂及血液流变指标有不同程度改善。结论舒血宁注射液是银杏叶提取制剂,其主要成分为银杏黄酮甙和银杏内酯等多种活性物质,能安全有效地治疗老年缺血性脑卒中。     

血肿微创抽吸术加用舒血宁注射液治疗81例高血压脑出血

目的探讨血肿微创抽吸术加用舒血宁注射液治疗高血压脑出血的疗效。方法将160例高血压脑出血患者随机分为两组,舒血宁组(治疗组)81例和对照组(单纯抽吸组)79例。两组在出血后3d行血肿微创抽吸术,舒血宁治疗组抽吸术后在常规治疗同时加用舒血宁注射液治疗;对照组在抽吸术后给予常规治疗,血肿抽吸术后治疗4周观察两组临床疗效,评估治疗前后神经功能缺失程度、血肿吸收程度治疗后变化。结果治疗两周后,舒血宁治疗组和对照组比较显效率有统计学意义(P=0.002),有效率无统计学意义(P=0.526)。治疗组血肿体积和神经功能缺损程度评分均低于对照组(P<0.05)。结论舒血宁注射液能促进高血压脑出血患者血肿抽吸术后残留血肿的吸收,并明显改善神经功能。     

补肾益脑通络胶囊治疗缺血性脑卒中226例

目的观察补肾益脑通络胶囊治疗缺血性脑卒中的临床疗效.方法将386例缺血性脑卒中病人随机分为治疗组226例和对照组160例,治疗组在西药常规治疗基础上服用补肾益脑通络胶囊,对照组采用西药常规治疗.所有病人治疗前后均进行神经功能缺损程度评分测定,并做血液流变学、血脂检查.结果治疗组总有效率为93.8%,愈显率为76.1%;对照组总有效率为71.3%,愈显率为41.3%,两组疗效比较,有统计学意义(P＜0.01).两组病人神经功能缺损程度评分和血液流变学、血脂各项指标治疗后均有改善,且治疗组优于对照组(P＜0.05～P＜0.01).结论补肾益脑通络胶囊治疗缺血性脑卒中临床疗效确切,与西药配合应用明显优于单纯西药治疗.     

银杏叶提取物注射液对老年缺血性脑卒中患者血流动力学效应的影响及预后评价

目的探讨银杏叶提取物制剂(舒血宁)对老年缺血性脑卒中(IS)患者血流动力学效应的影响及其预后情况。方法将160例老年IS患者按照入院顺序随机分为两组,舒血宁组和常规治疗组各80例。舒血宁组给予传统治疗联合静滴舒血宁;常规治疗组予单独传统治疗,均采用双盲对照。结果舒血宁组临床有效率为88.75%,显著高于常规治疗组(P<0.05)。经格拉斯哥、中国脑卒中量表及加拿大神经学评估表三种方式进行的预后评分均发现舒血宁组预后评分显著高于常规治疗组(P<0.05),且长期随访结果亦显示,舒血宁组IS复发率为5.00%,显著低于常规治疗组(P<0.05)。同时,血流动力学效应指标也相继反映舒血宁组IS患者血液循环改善情况优于常规治疗组(P<0.05)。结论舒血宁注射液对老年IS患者具有较佳的疗效且预后良好,且舒血宁主要通过改善机体血液循环体系发挥药理作用。     

急性缺血性脑卒中患者血浆脑钠肽水平与神经功能缺失的关系

目的 分析急性缺血性脑卒中患者入院时血浆脑钠肽(BNP)水平与神经功能缺失严重程度的关系.方法 随机选择88例急性缺血性脑卒中患者,根据美国国立卫生院神经功能缺损评分(NIHSS)分为急性期神经功能缺失严重组(NIHSS评分≥8分)与急性期神经功能缺失轻症组(NIHSS评分＜8分)两组,测定患者人院时血浆BNP水平并进行比较,将急性缺血性脑卒中患者急性期神经功能缺失严重程度相关的多个变量采用单因素Logistic回归分析.结果 入院时NIHSS评分与梗死体积、入院时BNP值均明显相关(P＜0.01),急性期神经功能缺失严重组血浆BNP水平明显高于急性期神经功能缺失轻症组(P＜0.01).血浆BNP水平≥634.15 pg/ml可以作为急性期神经功能缺失较严重(NIHSS评分≥8分)的预测指标,其敏感性为86.96％,特异性为86.15％.结论 急性缺血性脑卒中患者入院时血浆BNP水平可作为急性期神经功能缺失严重程度的预测因子.     

小组模式干预对城市社区卒中后偏瘫患者生活质量的影响

目的评估小组模式干预对城市社区卒中后偏瘫患者生活质量的影响。方法纳入80例首次发病的卒中出院患者,按照是否进行小组模式干预随机分为干预组和对照组,每组40例。干预组患者接受小组模式干预治疗,包括卒中教育、康复训练、文体疗法等措施;对照组仅接受基础治疗。采用卒中生活质量（SS—QOL）量表和偏瘫肢体的运动功能（FIM）量表,评估两组患者入组时和3个月后的疗效情况。结果①人组时,两组患者的SS—QOL、FIM评分比较,差异无统计学意义,P〉0．05。②干预后3个月,干预组患者的SS—QOL、FIM评分均高于入组时的评分,差异有统计学意义,P〈0．05;对照组患者的SS—QOL、FIM评分也均高于入组时的评分,差异有统计学意义,P〈0．05。③干预后3个月,干预组患者的SS—QOL、FIM评分均高于对照组的评分,差异有统计学意义,P〈0．05。结论采用小组模式对城市社区卒中后偏瘫患者进行干预,能改善患者的生活质量和预后。     

血管活性物质与急性脑梗死的相关性及脑局部亚低温治疗对其的影响

目的 探讨血管活性物质在脑梗死发生、发展中的作用及局部亚低温治疗的效果。方法 将73例急性重症脑梗死患者分为亚低温组36例及常规组37例;两组均予常规治疗,亚低温组加用脑局部亚低温治疗。检测两组治疗前后血清血管活性物质神经肽（NPY）、降钙素基因相关肽（CGRP）、神经降压素（NT）、内皮素（ET-1）水平,并与32例健康人（对照组）比较,治疗前后行临床神经功能缺失评分。结果 73例患者治疗前NPY、CGRP、NT、ET-1均明显高于对照组;治疗后7、15d逐渐下降;亚低温组明显低于常规组（P〈0．05）;治疗30d亚低温组临床神经功能缺失评分明显低于常规组（P〈0．01）。结论 血管活性物质在脑梗死发生、发展中起重要作用;局部亚低温治疗可促进急性脑梗死患者神经功能缺损恢复,明显改善预后;其可能机制为调节血管活性物质水平。     

Effect of Yiqihuoxue Formula for the treatment of ischemic stroke: A retrospective study

This retrospective study assessed the feasible effect of Yiqihuoxue Formula (YQHXF) for the treatment of patients with ischemic stroke (IS).A total of 66 patients with IS were included in this retrospective study. All patients received routine treatment, and were divided into two groups: a treatment group (n = 33) and a control group (n = 33). In addition to the routine treatment, all patients in the treatment group also underwent YQHXF treatment. All patients in both groups were treated for a total of 8 weeks. The outcomes were assessed by National Institute of Health Stroke Scale (NIHSS), modified Rankin scale (mRS), Barthel index scale (BIS), stroke-specific quality of life (SS-QOL) scale, and adverse events. All outcomes were measured before and after the treatment.After treatment, patients in the treatment group showed better improvements in NIHSS scale (P = .01), mRS (P < .01), BIS (P = .04), and SS-QOL scale (P = .04), than patients in the control group. No treatment-associated adverse events were recorded in this study.The results of this study indicated that YQHXF may benefit for patients with IS.     

卡维地洛对慢性心力衰竭患者血浆内皮素及降钙素基因相关肽的影响

目的　观察卡维地洛对慢性心力衰竭 (CHF)患者血浆内皮素 1(ET 1)、降钙素基因相关肽 (CGRP)水平的影响。方法　将 6 0例CHF患者分成卡维地洛组和常规治疗组进行对照 ,测定两组患者在用药前及用药 6个月后血浆ET 1、CGRP水平变化 ,并与正常对照组 (2 0例 )进行对照。结果　CHF患者血浆ET 1较正常对照组明显升高(P <0 .0 1) ,血浆CGRP则明显降低 (P <0 .0 5 ) ;卡维地洛组治疗后血浆ET 1较治疗前明显下降 (P <0 .0 1) ,血浆CGRP治疗后较治疗前明显升高 ;常规治疗组治疗后血浆ET 1、CGRP水平的变化差异无显著性意义。结论　卡维地洛对心力衰竭患者的血浆ET 1有降低作用 ,对血浆CGRP有升高作用     

Oral budesonide therapy improves quality of life in patients with collagenous colitis

Introduction Collagenous colitis is an idiopathic microscopic colitis characterised by watery diarrhoea. The impact of collagenous colitis on quality of life has not been assessed. Our aim was to assess quality of life in patients with this condition and compare the effect of treatment with budesonide capsules or placebo on this parameter.Methods Patients with chronic diarrhoea and histologically-proven collagenous colitis were randomised to receive either budesonide controlled-release capsules (Entocort capsules, AstraZeneca, Lund, Sweden), 9 mg/day, or placebo for 6 weeks. Quality of life was measured using the validated Gastrointestinal Quality of Life Index (GIQLI) at baseline and after 6 weeks. With the GIQLI, scores range from 0 to 144, with higher scores representing better quality of life.Results Complete quality of life assessment was available in 29 patients (budesonide: n=17; placebo: n=12). At baseline, quality of life was low in patients with collagenous colitis (mean 76). After 6 weeks of treatment, the mean GIQLI score increased significantly in the budesonide group (from 67 to 92, p<0.001), but remained unchanged in the placebo group (86–88). The mean score of the dimensions symptoms (p=0.001), emotional functioning (p=0.003) and physical functioning (p=0.017) increased significantly in the budesonide group compared with the placebo group. A significantly larger proportion of patients in the budesonide group experienced improved stool consistency (p<0.01) and a significant reduction in the mean stool frequency compared with those in the placebo group (p<0.01).Conclusion Quality of life is seriously reduced in patients with collagenous colitis. Six-week treatment with oral budesonide controlled-release capsules significantly improves quality of life and clinical symptoms compared with placebo in these patients.     

无症状性脑梗死患者的认知功能状态分析

目的探讨无症状性脑梗死患者的认知功能状态。方法选择缺血性脑卒中患者227例,其中无症状性脑梗死患者92例(无症状性脑梗死组)和临床缺血性脑梗死患者135例(临床缺血性脑梗死组),使用蒙特利尔认知评估量表(Montreal cognitive assessment,MoCA)和简易智能状态检查量表(mini-mental state examination,MMSE)评估认知功能,比较2组患者认知功能的差异。结果无症状性脑梗死组与临床缺血性脑梗死组MMSE和MoCA总分差异无统计学意义(P>0.05);无症状性脑梗死组MMSE即刻记忆评分明显低于临床缺血性脑梗死组[(2.91±0.28)分vs(2.96±0.24)分,P<0.05],其他各认知领域评分差异无统计学意义(P>0.05)。结论与临床缺血性脑梗死一样,无症状性脑梗死也可引起认知功能障碍。     

Clinical efficacy of tianeptine in patients with ischemic heart disease and comorbid depression

Ischemic heart disease patients (20 men, 20 women, age 36-72 years) with class II-III effort angina and depression (Beck Depression Inventory -- BDI -- score > or = 19) were randomized to standard therapy were treatment of stable ischemic heart disease (control group) or standard therapy plus tianeptine 37.5 mg/day. After 6 weeks 52% decrease of BDI score occurred in tianeptine treated patients (from 24.9+/-1.2 to 11.9+/-1.5, p<0.001). This was associated with decrease of number and severity of cardialgias, better blood pressure control in patients with hypertension, lengthening of exercise time during exercise test (by 3.3+/-0.9 min, p<0.05), and increase of overall index of quality of life (by 2.6+/-0.9 points, p<0.01). No dynamics of these parameters occurred in control group.     

脑出血早期康复治疗后对生存质量的影响

目的脑出血早期康复治疗后,随访康复治疗对生存质量的影响。方法收集原发性脑出血患者174例,均于发病后1、3、6、12个月进行随访。完成4次随访的患者分为康复组(102例)和对照组(72例),分别对临床神经功能缺损程度(neurological defict,ND)、肢体运动功能(采用Fugl-Meyer评分)和脑卒中生存质量(SS-QOL)进行比较。结果康复组在1、3、6、12个月ND评分、Fugl-Meyer评分和SS-QOL总分均明显高于对照组(P<0.05)。发病1个月康复组的生存质量在精力、活动、自理能力、上肢功能这4个因子的评分明显高于对照组,3个月时除上述4个因子外,增加了家庭角色、工作(劳动)2个因子,6个月时除上述6个因子外,增加了社会角色、语言2个因子,12个月时除上述8个因子外,又增加了情绪、个性、思维3个因子共11个因子较对照组有明显改善(P<0.05)。结论早期康复治疗脑出血可以显著改善神经功能缺损程度、肢体运动功能和生存质量。     

The impact of asthma on quality of life and anxiety: a pilot study

Introduction: Asthmatic patients are at risk for psychiatric symptoms. The objective of this study is to test the hypothesis that asthmatics have worse quality of life and anxiety scores in relation to a control group. Methods: This study is a cross-sectional study in which quality of life and anxiety scores were compared in a sample of 102 individuals, 51 asthmatics and 51 non-asthmatics. Quality of life and anxiety scores were quantified using validated questionnaires. The differences between the averages and the correlations between the total score for quality of life and anxiety were compared with t-tests and Pearson's correlation tests, respectively. The odds ratio compared the prevalence of moderate and severe anxiety between the groups. Results: The asthma group had higher average anxiety (p?<?0.001) and lower averages in all areas of quality of life: physical functioning, physical role functioning, bodily pain, general health, vitality, social functioning, emotional role functioning and mental health (p?<?0.05 for all variables). There was a significant and inverse correlation between the total score for quality of life and anxiety scores but only in the asthma group (r?=??0.71). Conclusions: Asthmatics have worse indicators of quality of life and anxiety, even though the symptoms of asthma are under clinical control. Moreover, the inverse correlation between the quality of life and the average anxiety scores in the asthma group suggests that the pulmonary inflammatory process of asthma may be related to the pathophysiology of emotional commitment in that group.     

冠脉重建术后患者康复运动对ET-1、NO和CGRP的影响

目的:观察康复运动治疗对冠心病患者冠脉重建术后内皮素(ET-1)、一氧化氮(NO)及降钙索基因相关肽(CGRP)水平的影响,以进一步探讨康复运动治疗对冠心病患者内皮功能的作用。方法:选择56例经皮冠状动脉腔内成形术(PTCA),10例冠脉搭桥术(CABG)后患者,按随机原则此66例患者被分配入康复运动治疗组和常规治疗组,每组33例。两组临床特征无统计学差异,有可比性。两组患者均给予相同的常规药物治疗,康复运动治疗组还接受12周康复运动治疗。观察疗程前后两组ET-1、NO及CGRP水平的变化。结果:康复运动治疗组12周疗程前、后ET-1、NO及CGRP水平均有显著性差异(P<0.05)。治疗后康复运动组与常规治疗组的ET-1、NO、CGRP水平均有显著性差异(P<0.05)。而常规治疗组疗程前、后ET-1、NO、CGRP水平均无显著性差异(P>0.05)。结论:康复运动治疗可以改善冠心病冠脉重建术后患者的血管内皮功能。